What is Assertio?
Founded in 1995, Assertio is a commercial pharmaceutical company dedicated to the development and marketing of branded prescription medications. The company's therapeutic focus spans neurology, inflammation, and pain management, areas critical to patient care. Assertio has strategically expanded its product portfolio through a combination of acquisitions, licensing agreements, and mergers, demonstrating a proactive approach to market positioning. Operating globally across North America, Europe, and Asia, Assertio is committed to delivering differentiated pharmaceutical products and pursuing growth opportunities in diverse therapeutic areas.
How much funding has Assertio raised?
Assertio has raised a total of $41.5M across 2 funding rounds:
Stock Offering
$7.2M
Share Placement
$34.3M
Stock Issuance/Offering (1997): $7.2M, investors not publicly disclosed
Share Placement (2021): $34.3M, investors not publicly disclosed
What's next for Assertio?
The recent major strategic investment signals Assertio's transition into a scaling phase, likely focused on expanding its market reach, advancing its product pipeline, and potentially exploring new therapeutic avenues. This capital will be instrumental in furthering its mission to provide innovative treatments and solidify its position as a key player in the pharmaceutical industry. Future endeavors may include further portfolio diversification and enhanced global operational capabilities.
See full Assertio company page
